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Abstract: Elevated plasma homocysteine
concentration either in fasting state or after
methionine loading is an independent risk
factor for vascular disease. The aim of this
study was to evaluate the relationship
between fasting total homocysteine (tHcy)
and post-methionine load tHcy in healthy
control subjects and in patients with
angiographically defined coronary artery
disease (CAD). Methionine loading has been
used to investigate impaired methionine
metabolism, especially of the transsulphuration pathway. We investigated the
effect of methionine excess on total plasma
homocysteine in 65 control subjects (44 men
and 21 women) who attended a polyclinic of
Gülhane Military Medical Academy (GMMA) in
Ankara. Forty-one patients (30 male, 11
female)
who
underwent
cardiac
catheterisation at GMMA formed the patient
group.
Plasma
total
homocysteine
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Introduction
Cardiovascular disease is the leading cause of
mortality in most Western countries. Hypertension,
diabetes, hyperlipidaemia, obesity and smoking are the
main risk factors for atherosclerosis and its thrombotic
complications. However, these factors alone cannot
account for all of the deaths caused by vascular
pathologies.
Homocysteine is a sulphur-containing amino acid
derived from the metabolism of methionine, an essential
amino acid. Total homocysteine can be metabolised via
the sulphuration pathway to form methionine. Only a
small amount of total homocysteine circulates freely, and
most of it is protein bound. Hyperhomocystinaemia
results from an inhibition of the remethylation pathway
or from an inhibition or a saturation of the transsulphuration pathway in homocysteine metabolism.
However, folate, vitamin B12 and vitamin B6 deficiency are
believed to be the major determinants of the increased

concentrations were measured by using high
pressure liquid chromatography with
fluorescence detection. The expected increase
in plasma homocysteine was found in both
men and women in the control and CAD
groups. In three of 21 women and three of
44 men with the methionine-loading test,
plasma homocysteine levels were higher than
30 µmol/l. In conclusion, it is thought that
methionine loading mainly stresses catabolism
through homocysteine trans-sulphuration;
therefore, oral methionine loading in CAD
patients leads to a higher accumulation of
homocysteine in plasma than in healthy
subjects, indicating that abnormal tHcy
response after methionine loading may be a
sensitive test for the diagnosis of CAD and the
genetic defects of the Hcy metabolism.
Key Words: Homocysteine, methionine,
coronary artery disease.

risk of cardiovascular
hyperhomocystinaemia (1).

disease

related

with

Homocysteine concentrations rise with age in both
sexes. Women in general have lower concentrations than
men, though these rise with menopause, cigarette
smoking, a high intake of caffeine or alcohol, a sedentary
lifestyle, various cancers, end-stage renal disease,
hypothyridism, inflammatory bowel disease, following
organ transplantation, and the use of inhibitors of folate
such as methotrexate and carbamazepine, or antagonists
of folate absorbtion such as colestipol and cholestyramine
(1-2). The modification of dietary patterns can have also
substantial effects on fasting levels of total serum
homocysteine (3).
Many clinical and epidemiologic studies have shown a
relation between total homocysteine levels and coronary
artery disease, peripheral artery disease, stroke and
venous thrombosis (4-12). The prevailing view of the
pathogenesis of coronary atherosclerosis is that it is
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followed by unstable angina, myocardial infarction or
sudden death. The acute event is frequently due to the
rupture or erosion of an atherosclerotic plaque associated
with thrombus formation (13-14). There is increasing
evidence that homocysteine may affect the coagulation
system and the resistance of the endothelium to
thrombosis (15), and that it may interfere with the
vasodilator and antithrombotic functions of nitric oxide
(16). Notably, the vascular complications reported in
patients with homocystinuria are related to thrombosis
rather than to atherosclerosis (17,18).
The methionine-loading test is used to reveal
additional abnormalities of the homocysteine metabolism
not detected by homocysteine concentration
measurements obtained in the fasting state. An abnormal
postmethionine-load homocysteine elevation above
fasting levels must be taken into account in the general
identification of patients bearing trans-sulphuration
defects such as vitamin B6 deficiency subjects or
heterozygotes for cystathionine ß-synthase (CBS)
deficiency.
Based on recent retrospective, prospective and
experimental studies, mild to moderate elevations of
fasting or post-methionine-load plasma homocysteine are
considered independent risk factors for cardiovascular
diseases in both men and women (19-21).
Our purpose was to evaluate the relationship between
fasting total homocysteine (tHcy) and post-methionine
load tHcy in healthy control subjects and in patients with
angiographically defined coronary artery disease. We
performed the methionine-loading test to also clarify the
risk of vascular disease due to hyperhomocystinaemia in
which a hidden risk of homocystinaemia caused by
heterozygous error in an enzyme needed in this particular
metabolic pathway can be made visible.

Materials and Methods
Subjects: From June 2000 through October 2001,
65 patients (44 men and 21 women) who attended a
polyclinic of Gülhane Military Medical Academy (GMMA)
in Ankara were enrolled as controls. All subjects
underwent a comprehensive history and physical
examination by a physician and completed a
questionnaire. None of the subjects had uremic renal
disease or used anticonvulsants. Control patients had no
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prior history of coronary heart disease (CHD) or
symptoms compatible with angina pectoris and had
normal resting electrocardiograms.
Forty-one patients (30 male, 11 female) who
underwent cardiac catheterisation at GMMA due to
clinical suspicion of CHD and who had > 50% occlusion in
at least one coronary artery were taken for this study.
Those who had had any acute coronary syndrome in the
previous 6 months were not included in this study.
Blood Collection: Blood samples were collected after
12-h fasting to perform routine tests. Samples were
obtained on the day before the angiography in the patient
group. Blood specimens containing EDTA for
homocysteine assay were placed on ice within 10 min of
collection and blood specimens containing no
anticoagulant for vitamin B12 and folic acid and were
allowed to clot for 30 min. Serum and plasma samples
were subsequently centrifuged at 2000 g in a
refrigerated centrifuge for 15 min and stored at –70 ºC
until analysis.
*Methionine-Loading Test: Methionine was
administered at a dose of 0.1 g/kg body weight in 200 ml
of orange juice after 12 h fasting. Blood was collected
immediately before and 2 and 6 h after methionine
intake. All subjects received a standardised diet containing
only foods low in methionine and folate from the evening
before until 24 h after methionine intake. EDTA blood
samples for post-methionine load homocysteine
determination were placed on ice after collection and
processed within 30 min. All samples were stored at –70
ºC until analysis. The study protocol was approved by the
committee for the protection of human subjects of
GMMA.
Chromatographic Equipment and Chemicals. We
used a Hewlett Packard model 1050 HPLC pump, HP
1100 fluorescence detector and HP 3396 pump
integrator (Aromolale, PA, USA). Methionine was
obtained from Ajinomoto (Japan). All of the chemicals
were of analytical grade and obtained from Sigma (St
Louis, USA) and Merck (Darmstadt, Germany)
Analysis of Plasma Homocysteine. Plasma total
homocysteine was measured by a kit for homocysteine
from Chromsystems (Germany).
The compounds were separated on a 4.6 x 150 mm
Chromsystems ODS-2 reverse phase column with a 5 µm
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Table. Characteristics of halthy control and CAD subject patients.

spherisorb ODS-2 silica cartridge guard column (Alltech,
Deerfield IL USA). Isocratic elution was performed at a
flow rate of 1.7 ml/min with mobile phase.
A five-point calibration curve was obtained using five
levels of standards. The correlation between the peak
area and the concentration was r: 0.9986.
Retention times for the total homocysteine and
internal standards were 2.3 and 4.1 min, respectively.
Statistical Methods. Differences in mean values
(mean ± standard error) between the patient and control
groups were tested by Student’s t test.

Healthy subjects

CAD subjects

Sex (M/F)

44/21

30/11

Age (Years)

33.4 ± 8.5

53.8 ± 12.9

Fasting Homocysteine (µmol/l)

7.17 ± 2.3

13.75 ± 4.5

Postload Homocysteine (µmol/l)

21.27 ± 6.2

35.14 ± 8.7

Vitamin B12 (pg/l)

397.52 ± 93.3

264.88 ± 76.8

Folic Acid (ng/l)

10.08 ± 2.2

5.77 ± 1.2

Mean Folate/Homocysteine Rate (x 103)

1.40

0.42

Preload > 12.0 µmol/l

4

14

After load > 30.0 µmol/l

6

20

Number with Hyperhomocystinaemia:

Results
The baseline charecteristics and parameter levels of
the study participants are shown in Table. Three of 21
healthy female subjects, and one of 44 healthy male
subjects had higher fasting plasma homocysteine levels of
12 µmol/l (Figure 1A). However, in three of 21 women
and three of 44 men who had standard methionineloading test plasma homocysteine levels were higher than
30 µmol/l. (Figure 1B) The peak post-methionine-loading
serum levels of plasma homocysteine in controls and CAD
patients are shown in Figures 2 and 3.

Discussion
This study set out to investigate the effect of
methionine loading on plasma homocysteine levels in
healthy control and CAD subjects. We used the
methionine-loading test to reveal additional abnormalities
of
the
homocysteine
metabolism.
Hyperhomocysteinaemia is associated with an increased
risk of atherosclerotic vascular disease and
thromboembolism in both men and women. In 1976,
Wilcken and Wilcken (22) published the first results
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Figure 1. Plasma fasting and after load homocysteine levels in controls and in patients with CAD.
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Plasma fasting and after load homocysteine levels in CAD
patients.

suggesting that even mild hyperhomocysteinaemia could
play a possible role in the pathogenesis of coronary artery
disease. They showed that about 30% of young patients
with angiographically proven coronary artery disease
demonstrated mild hyperhomocysteinaemia after a
methionine load. Murphy-Chutorian et al. (23) reported
methionine intolerance in 16 of 99 patients with coronary
heart disease.
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Previous studies have suggested that postmethionine-load homocysteine in the absence of fasting
hyperhomocystinaemia could account for over 40% of all
hyperhomocystinaemic persons (24). This was only
partially confirmed in our CAD patients, as suggested by
the presence of six CAD patients (22%) who presented
with impaired methionine tolerance and increased
homocysteine after the load test. If we take into account
how methionine intake could be higher than the metabolic
capacity, impaired methionine tolerance could be a
problem in CAD patients. Previous studies (25,26) have
demonstrated that methionine-rich meals normally cause
a slight increase in the plasma homocysteine
concentration. Diets, particularly rich in eggs may contain
a methionine intake (up to 2 g/day) that is higher than
normal metabolic capacity (~1 g/day). This indicates a
transient but constant increase in homocysteine
concentrations.
Boers et al. (15), using a methionine-loading test,
identified hyperhomocystinaemia in 14 of 50 patients
(28%) with premature peripheral and cerebral arterial
disease under 50 years of age. Brottstrom et al. (7)
reported methionine intolerance in 26 of 72 patients
(36%) with cerebrovascular disease who were under 55
years of age. Malinow et al. (15) detected higher fasting
serum total homocysteine levels in 47 patients with
occlusive peripheral vascular disease than in normal
subjects. Araki et al. (27) found elevated serum
homocysteine levels in 45 patients with cerebral
infarction as compared with 45 normal subjects, 45
patients with hypertension and 20 patients with cerebral
bleeding.
In
our
study,
the
proportion
of
hyperhomocystinaemia was higher in the angiographically
defined
CAD
patient
group.
In
contrast,
hyperhomocystinaemia was rare in our control group,
with only three of 21 normal female subjects and one of
44 normal male subjects having a fasting plasma
homocysteine levels higher than 12 µmol per liter. The
principal finding of this study is the observation of
hyperhomocystinaemia in 34% of patients with
angiographically defined CAD. The high rate of
hyperhomocystinaemia occurrence in our patient group is
similar to the findings of Boers et al. (19), who observed
elevated homocysteine in 21% of coronary heart disease
patients and 32% of venous thrombosis patients. Blacher
et al. (20) also observed that a significant percentage
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(15%) of their coronary heart disease patients were
hyperhomocystinaemic. This contradicts the study
published by Amundsen et al. (28), who found no
difference in fasting homocysteine levels between
controls and coronary heart disease patients.
An inverse relation between both serum folate levels
and serum vitamin B12 concentrations and
hyperhomocystinaemia has been reported by several
authors (29). In our study, low folate and vitamin B12
status were defined as a concentration below 3 µg/l and
180 ng/l respectively and hyperhomocystinaemia
correlated with reduced folate and B12 levels. The mean
folate and vitamin B12 levels for CAD groups were
significantly lower than those of the control group. This
suggests that increases in homocysteine may cause a
reduction in 5-methyltetrahydrofolate, which results
from a disturbed remethylation pathway, preventing the
normal conversion of 5-methyltetrahydrofolate to
methionine. This must be considered in evaluating the
relationship between folate and homocysteine in vascular
disease.
The mean folate/homocysteine rates in the CAD group
were substantially lower than those of the control group.
This reflects an increased body burden of homocysteine
per unit quantity of folate. Homocysteine in plasma
reflects the status or activity in only one folate-dependent
pathway. Elevated homocysteine levels can indicate a
reduced regeneration of methionine; however, this can
also be due to vitamin B12 deficiency or to genetic defects

in the enzymes of the trans-sulphuration pathway, which
can also contibute to hyperhomocystinaemia. These
confounding factors make it difficult to prove conclusively
that folate deficiency alone is the cause of
homocystinaemia in a particular patient. The
folate/homocysteine ratio may prove useful in
determining a relative lack of folate in the absence of
severe folate deficiency.
In conclusion, elevated plasma homocysteine
concentration, either in the fasting state or after
methionine loading, is an independent risk factor for
vascular disease. Methionine loading may be used to
investigate the impaired methionine metabolism,
especially of the trans-sulphuration pathway, and to
reveal additional abnormalities of the homocysteine
metabolism.
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